Response-guided therapy for patients with hepatitis C virus genotype 6 infection: A pilot study

Journal of Viral Hepatitis

Volumn 19, Issue 6, 2012, Pages 423-430

  Tangkijvanich, P ^a   Komolmit, P ^a   Mahachai, V ^a   Poovorawan, K ^a   Akkarathamrongsin, S ^a   Poovorawan, Y ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

genotype 6; hepatitis C; RVR; treatment duration; virological response

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG MONITORING; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84861097299     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01566.x     Document Type: Article

References (31)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl. 1): 74-81.
2. Argentini C, Genovese D, Dettori S, Rapicetta M,. HCV genetic variability: from quasispecies evolution to genotype classification. Future Microbiol 2009; 4 (3): 359-373.
3. Fishman SL, Branch AD,. The quasispecies nature and biological implications of the hepatitis C virus. Infect Genet Evol 2009; 9 (6): 1158-1167.
4. Chao DT, Abe K, Nguyen MH,. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 2011; 34 (3): 286-296.
5. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, et al. Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. J Med Virol 2010; 82 (2): 257-262.
6. Sunanchaikarn S, Theamboonlers A, Chongsrisawat V, et al. Seroepidemiology and genotypes of hepatitis C virus in Thailand. Asian Pac J Allergy Immunol 2007; 25 (2-3): 175-182. (Pubitemid 350081449)
7. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, MD) 2009; 49 (4): 1335-1374.
8. Nguyen NH, VuTien P, Garcia RT, et al. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat 2010; 17 (10): 691-697.
9. Tsang OT, Zee JS, Chan JM, et al. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J Gastroenterol Hepatol 2010; 25 (4): 766-771.
10. Zhou YQ, Wang XH, Hong GH, et al. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. J Viral Hepat 2011; 18 (8): 595-600.
11. Seto WK, Lai CL, Fung J, et al. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010; 53 (3): 444-448.
12. Fung J, Lai CL, Hung I, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008; 198 (6): 808-812.
13. Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology (Baltimore, MD) 2010; 52 (5): 1573-1580.
14. de Leuw P, Sarrazin C, Zeuzem S,. How to use virological tools for the optimal management of chronic hepatitis C. Liver Int 2011; 31 (Suppl. 1): 3-12.
15. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135 (2): 451-458.
16. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (Baltimore, MD) 2006; 43 (5): 954-960. (Pubitemid 43724620)
17. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44 (1): 97-103. (Pubitemid 41772522)
18. Antaki N, Marcellin P,. What is the safe duration of therapy for patients infected with HCV genotype 6? Nat Clin Pract 2009; 6 (2): 78-79.
19. Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30 (3): 342-355.
20. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL,. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003; 187 (7): 1071-1074. (Pubitemid 36399349)
21. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W,. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology (Baltimore, MD) 2002; 36 (5): 1259-1265. (Pubitemid 35253444)
22. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB,. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103 (5): 1131-1135. (Pubitemid 351677993)
23. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S,. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55 (1): 69-75.
24. Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology (Baltimore, MD) 2008; 47 (1): 35-42. (Pubitemid 351171039)
25. Mangia A, Bandiera F, Montalto G, et al. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. J Hepatol 2010; 53 (6): 1000-1005.
26. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology (Baltimore, MD) 2008; 47 (6): 1884-1893.
27. Di Martino V, Richou C, Cervoni JP, et al. Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized controlled trials and implications for the future. Hepatology (Baltimore, MD) 2011; 54 (3): 789-800.
28. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357 (2): 124-134. (Pubitemid 47057730)
29. Mangia A,. Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. Liver Int 2011; 31 (1): 36-41.
30. Martin P, Jensen DM,. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 2008; 23 (6): 844-855. (Pubitemid 351806583)
31. Nguyen NH, Vutien P, Trinh HN, et al. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hep Intl 2010; 4 (2): 523-529.